Form 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 1997
Commission File No. 000-19495
Embrex, Inc.
---------------------------------------------------
(Exact name of registrant as specified in its charter)
North Carolina 56-1469825
- -------------------------------------------------------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
1035 Swabia Court, Durham, NC 27703
--------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone no. including area code: (919) 941-5185
Check whether the registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
Yes X No
---- ----
The number of shares of Common Stock, $0.01 par value, outstanding as of October
31, 1997, was 8,235,949.
<PAGE>
EMBREX, INC.
INDEX
<TABLE>
<CAPTION>
Page
----
<S> <C>
Part I
Financial Information:
Item 1: Financial Statements
Balance Sheets.....................................................................3 of 12
Statements of Operations...........................................................4 of 12
Statements of Cash Flows...........................................................5 of 12
Notes to Consolidated Financial Statements.........................................6 of 12
Item 2:
Management's Discussion and Analysis of
Financial Condition and Results of Operations......................................7 of 12
Item 3:
Quantitative and Qualitative Disclosures
About Market Risk.................................................................10 of 12
Part II
Other Information:
Item 1: Legal Proceedings.................................................................10 of 12
Item 2: Changes in Securities.............................................................10 of 12
Item 3: Defaults Upon Senior Securities...................................................10 of 12
Item 4: Submission of Matters to a Vote of Security Holders...............................10 of 12
Item 5: Other Information.................................................................10 of 12
Item 6: Exhibits and Reports on Form 8-K..................................................10 of 12
Signatures 11 of 12
Exhibit Index.............................................................................12 of 12
</TABLE>
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements
Embrex, Inc.
CONSOLIDATED BALANCE SHEETS
(DOLLARS IN THOUSANDS)
<TABLE>
<CAPTION>
SEPTEMBER 30 DECEMBER 31
1997 1996
---------- ----------
(UNAUDITED)
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents .......................................... $ 9,338 $ 9,036
Short-term investments ............................................. 0 876
Inventories:
Materials and supplies ......................................... 854 1,061
Product ........................................................ 493 573
Accounts receivable - trade ........................................ 2,788 2,313
Other current assets ............................................... 515 124
-------- --------
TOTAL CURRENT ASSETS ........................................... 13,988 13,983
INOVOJECT(R)SYSTEMS UNDER CONSTRUCTION ................................. 651 530
INOVOJECT(R)SYSTEMS .................................................... 20,514 18,193
Less accumulated depreciation .......................................... (11,162) (8,499)
-------- --------
9,352 9,694
EQUIPMENT, FURNITURE AND FIXTURES ...................................... 3,000 2,607
Less accumulated depreciation and amortization ..................... (1,933) (1,695)
-------- --------
1,067 912
OTHER ASSETS:
Goodwill, patents, and exclusive licenses of patentable technology
(net of accumulated amortization of $70 in 1997 and $58 in 1996) 335 125
Other non-current assets ........................................... 79 310
-------- --------
TOTAL ASSETS ........................................................... $ 25,472 $ 25,554
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities
Accounts payable ................................................... $ 1,418 $ 1,355
Accrued expenses ................................................... 1,844 1,087
Current portion of capital lease obligations ....................... 2,692 3,080
Current portion of long-term debt .................................. 322 909
-------- --------
TOTAL CURRENT LIABILITIES ...................................... 6,276 6,431
CAPITAL LEASE OBLIGATIONS, less current portion ........................ 3,762 5,806
LONG-TERM DEBT, less current portion ................................... 12 8
SHAREHOLDER'S EQUITY Common Stock, $.01 par value:
Authorized - 30,000,000 shares
Issued and outstanding -
8,236,304 and 8,043,490 shares at September 30, 1997
and December 31, 1996, respectively ........................ 82 80
Additional paid-in capital ......................................... 54,765 53,742
Currency translation adjustments ....................................... 50 180
Accumulated deficit ................................................ (39,475) (40,693)
-------- --------
TOTAL SHAREHOLDERS' EQUITY ..................................... 15,422 13,309
-------- --------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY ............................. $ 25,472 $ 25,554
======== ========
</TABLE>
3
<PAGE>
Embrex, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
THREE MONTHS ENDED NINE MONTHS ENDED
SEPTEMBER 30 SEPTEMBER 30
------------------------------------------------
1997 1996 1997 1996
----------------------------------------------
<S> <C> <C> <C> <C>
REVENUES
INOVOJECT(R)SYSTEM revenue............................. $ 6,252 $ 5,188 $17,538 $ 14,129
Product sales.......................................... 246 408 745 1,043
Other revenue.......................................... 33 45 94 132
----------- -------- ------- --------
TOTAL REVENUES..................................... 6,531 5,641 18,377 15,304
COST OF PRODUCT SALES AND INOVOJECT(R)SYSTEM REVENUES...... 3,194 2,943 8,927 8,093
------- ------ ------ -------
GROSS PROFIT....................................... 3,337 2,698 9,450 7,211
OPERATING EXPENSES
General and administrative............................. 1,539 1,022 4,153 2,703
Sales and marketing.................................... 87 80 458 217
Research and development............................... 959 1,023 2,955 2,682
-------- ------ ------- ------------
TOTAL OPERATING EXPENSES........................... 2,585 2,125 7,566 5,602
OPERATING INCOME........................................... 752 573 1,884 1,609
OTHER INCOME (EXPENSE)
Interest income........................................ 118 94 363 250
Interest expense....................................... (260) (398) (865) (1,241)
-------- -------- --------- ----------
TOTAL OTHER EXPENSE................................ (142) (304) (502) (991)
-------- -------- ---------- --------
INCOME BEFORE TAXES........................................ 610 269 1,382 618
INCOME TAXES ........................................... 70 66 164 164
--------- --------- ---------- --------
NET INCOME .......................................... $ 540 $ 203 $ 1,218 $ 454
======== ==================================
Net income per share of Common Stock........................ $ .06 $ .03 $ .15 $ .06
========= ========= =====================
WEIGHTED AVERAGE SHARES OF
COMMON STOCK OUTSTANDING (in thousands).................. 8,369 7,442 8,327 7,266
</TABLE>
4
<PAGE>
Embrex, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(DOLLARS IN THOUSANDS)
<TABLE>
<CAPTION>
NINE MONTHS ENDED SEPTEMBER 30
1997 1996
---------- --------
<S> <C> <C>
OPERATING ACTIVITIES
Net income ........................................................... $ 1,218 $ 454
Adjustments to reconcile net income to net cash (used in) provided by
operating activities:
Depreciation and amortization .................................... 2,935 2,841
Changes in operating assets and liabilities:
Accounts receivable, inventories and other current assets .... (714) (760)
Accounts payable and accrued expenses ........................ 886 150
------- -------
NET CASH PROVIDED BY OPERATING ACTIVITIES ................................ 4,325 2,685
INVESTING ACTIVITIES
Purchases of short-term investments .................................. 876 97
Purchases of INOVOJECT(R)systems, equipment, furniture and fixtures .. (2,615) (3,692)
Decrease in other noncurrent assets .................................. 1 95
------- -------
NET CASH USED IN INVESTING ACTIVITIES .................................... (1,738) (3,500)
FINANCING ACTIVITIES
Issuance of common stock ............................................. 307 260
Proceeds from long-term debt ......................................... (160) 8
Proceeds from short-term debt ........................................ 0 468
Payments on short-term debt .......................................... 0 (30)
Proceeds from capital lease obligations .............................. 128 2,141
Payments on capital lease obligations .................................... (2,560) (2,020)
------- -------
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES ...................... (2,285) 827
------- -------
INCREASE IN CASH AND CASH EQUIVALENTS .................................... 302 12
Cash and cash equivalents at beginning of period ..................... 9,036 5,354
------- -------
CASH AND CASH EQUIVALENTS AT END OF PERIOD ............................... $ 9,338 $ 5,366
======= =======
</TABLE>
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING ACTIVITY:
During 1997, $425,000 of outstanding debentures along with $66,000 of accrued
interest were converted into 98,267 shares of Common Stock net of unamortized
debt issuance costs totaling $1,000. In addition, 419 shares of Embrex Common
Stock were issued pursuant to the non-cash exercise of warrants related to the
initial sale of such debentures.
5
<PAGE>
EMBREX, INC.
FORM 10-Q
September 30, 1997
NOTES TO CONSOLIDATED INTERIM CONDENSED FINANCIAL STATEMENTS (Unaudited)
NOTE 1 -- BASIS OF PRESENTATION
The accompanying unaudited financial statements include the accounts of Embrex,
Inc. and its wholly owned subsidiaries, Embrex Europe Limited and Embrex Sales,
Inc. (collectively referred to as the "Company") and have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and notes required
by generally accepted accounting principles. In the opinion of management, all
adjustments (consisting of normal recurring accruals) considered necessary for a
fair presentation of financial condition and results of operations have been
included. Operating results for the nine month period ended September 30, 1997
are not necessarily indicative of the results that may be attained for the
entire year. For further information, refer to the financial statements and
notes thereto included in the Company's Form 10-K for the year ended December
31, 1996.
NOTE 2 - NET INCOME PER SHARE
Net income or earnings per share (primary earnings per share) are computed by
dividing net income by the weighted average number of shares of Common Stock and
common stock equivalents outstanding during the period. Common stock equivalents
consist of stock options, warrants, and common shares purchasable under the
Employee Stock Purchase Plan and are computed using the treasury stock method.
In February 1997, the Financial Accounting Standards Board issued Statement No.
128, EARNINGS PER SHARE, which is required to be adopted on December 31, 1997.
At that time, the Company will be required to change the method currently used
to compute earnings per share and to restate all prior periods. Under the new
requirements for calculating primary earnings per share, the dilutive effect of
stock options will be excluded. The difference between primary and fully diluted
net income per common share is not significant in all periods presented. The
impact of Statement 128 on the calculation of fully diluted earnings per share
is not expected to be material.
NOTE 3 - RECLASSIFICATION
Certain 1996 amounts in the accompanying financial statements have been
reclassified to conform to the presentation format adopted in the fourth quarter
of 1996. These reclassifications had no effect on previously reported net
income, loss, or shareholders equity.
6
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.
RESULTS OF OPERATIONS
Three Months Ended September 30, 1997 and 1996
Consolidated revenues for the third quarter of 1997 totaled $6.5 million,
representing a 16.0% increase of $890,000 over the same period in 1996. During
this time, the Company achieved a 20.5% increase of approximately $1.1 million
in INOVOJECT(R) system revenue to $6.3 million from $5.2 million during the
comparable period in 1996. Substantially all of the 1997 and 1996 INOVOJECT(R)
system revenues were derived from INOVOJECT(R) system lease fees, with the
growth in lease revenues primarily due to a 9.5% year-over-year increase in the
number of INOVOJECT(R) systems operating under lease agreements. In addition,
third-quarter 1997 revenues included amounts attributable to the sale of
INOVOJECT(R) systems and parts to a foreign distributor.
The previously announced delay associated with obtaining British regulatory
approval for the sale of Bursamune(TM) in the United Kingdom has reduced the
Company's ability to generate revenue from product sales. Product sales declined
39.7% to $246,000 from the $408,000 recorded a year earlier, which included
sales in the 1996 period of the Company's proprietary viral neutralizing factor
(VNF(R)) product, which is a key component of Bursamune(TM), to Fort Dodge
Animal Health, a division of American Home Products. The purchase by Fort Dodge
reflected the then-anticipated British regulatory approval. Overall, the
Company's gross profit margin performance of 51% during the third quarter
exceeded the 48% level achieved during the comparable 1996 period.
Operating expenses increased to $2.6 million for the third quarter of 1997, up
$460,000 from the comparable 1996 amount. The increase, which principally
reflects stepped-up activity attributable to general corporate expense
associated with higher sales and legal fees pertaining to patent infringement
matters, was partially offset by a $64,000 reduction in product research,
development, and manufacturing services expenditures.
Net other expense decreased 53.3% from $304,000 in the 1996 period to $142,000
in 1997 due to the combination of diminishing interest expense payments on
INOVOJECT(R) system lease lines, and an increase in interest earned on invested
cash.
The stronger bottom-line performance demonstrates the benefit of the Company's
focus on achieving INOVOJECT(R) system operating efficiencies and constraining
selling expenses, the combination of which enabled the Company to post record
third quarter net income. Net income of $540,000 for the quarter ended September
30, 1997 increased to 266% of the $203,000 profit earned during the comparable
1996 period. Earnings per share doubled, to $.06 for the 1997 third quarter
versus $.03 per share in the comparable 1996 period. This improvement in
per-share earnings was achieved in spite of a 12.5% increase in the number of
weighted average shares of common stock outstanding to 8.369 million shares
compared to 7.442 million at the end of the third quarter of 1996, chiefly
reflecting the issuance of shares pursuant to the exercise of outstanding
warrants and convertible debentures.
7
<PAGE>
Nine Months Ended September 30, 1997 and 1996
Consolidated revenues for the nine months ended September 30, 1997 totaled $18.4
million, up 20% from $15.3 million a year earlier. This increase is principally
attributable to stronger INOVOJECT(R) system revenues which account for 95.4% of
the $18.4 million total. Consistent with the 9.5% increase from September 30,
1996 in the number of INOVOJECT(R) systems installed under lease agreements,
INOVOJECT(R) system revenues showed a year-over-year increase of 24.1%, growing
$3.4 million to $17.5 million. Substantially all of the 1997 and 1996
INOVOJECT(R) system revenues were derived from INOVOJECT(R) system lease fees.
Cost of product and INOVOJECT(R) system revenues totaled $8.9 million (48.6% of
total revenues) for the first nine months of 1997 compared to $8.1 million
(52.9% of total revenues) for the same 1996 period, resulting in nine-month
gross margins of 51.4% and 47.1%, respectively.
Operating expenses for the nine months ended September 30, 1997 increased to
$7.6 million, up $2.0 million from the comparable 1996 amount. The increase
principally reflects $1.5 million attributable to general corporate expense
related to higher sales and legal fees associated with patent infringement
matters; $241,000 relating to enlarging the installed base of INOVOJECT(R)
systems, as well as the cost of expanding the Company's Asian presence in
anticipation of the approval of vaccines for IN OVO delivery; and $273,000
associated with product research, development, and manufacturing activities.
Net other expense decreased by $489,000 from $991,000 for the nine months ended
September 30, 1996 to $502,000 for the same 1997 period. This 49.3% improvement
is the result of the combination of a $376,000 decrease in interest expense
attributable to reductions in lease and debt obligations, and a $113,000
increase in interest earned on invested cash.
Net income for the nine months ended September 30, 1997 of $1,218,000 represents
268% of the $454,000 reported for the same period ended September 30, 1996. The
increase of $764,000 translates into earnings during the first nine months of
1997 that, at $.15 per weighted average share of common stock outstanding,
equals 250% of the $.06 per weighted average share reported for the nine months
ended September 30,1996. This improvement in nine-month 1997 earnings was
accompanied by a 14.6% increase of 1.1 million in the number of weighted average
shares of common stock outstanding from 7.266 million at September 30, 1996 to
8.327 million at September 30, 1997, chiefly reflecting the issuance of shares
pursuant to the exercise of outstanding warrants and convertible debentures.
Management anticipates further revenue growth throughout the balance of 1997
relative to the levels achieved in 1996, although generally the year-over-year
rate of growth has slowed as compared with 1995 periods. Due to the Company's
substantial penetration of markets in the United States and Canada for its
INOVOJECT(R) system, revenue growth is expected to come primarily from new
INOVOJECT(R) system leases in other countries, product sales of VNF(R) to
vaccine manufacturers, and sales of its Bursaplex(TM) (previously known as
"BDA-BLEN") product to poultry producers.
The rate at which the marketplace will accept its INOVOJECT(R) system technology
outside the United States and Canada, the timing of approvals outside the United
States and Canada of third-party vaccines for IN OVO use, and levels of
INOVOJECT(R) system utilization by domestic and foreign hatchery operators will
impact the pace of revenue growth and the ability of the Company to sustain, or
improve, profitability from the installation and operational throughputs of
8
<PAGE>
INOVOJECT(R) systems. Management will continue to focus on operating
efficiencies and revenue growth in an effort to maintain or improve gross
margins, and will continue to carefully balance selling, operating, and interest
expenses against its goal of continuing and increasing profitability.
CHANGES IN FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
At September 30, 1997, the Company's cash, cash equivalents and short-term
investment balances totaled $9.3 million, down approximately $574,000 from the
$9.9 million on hand at year-end 1996. Embrex believes it will be able to
continue its use of existing cash in conjunction with cash flow generated by
operations to fund its capital needs and continued international expansion
during the balance of 1997.
Operating activities generated $4.3 million in cash during the first nine months
of 1997, reflecting increases attributable to $1,218,000 in net income, $2.9
million from depreciation and amortization, and $886,000 from increases in
accounts payable and accrued expenses, the total of which was then offset by
$714,000 chiefly attributable to increases in accounts receivable and other
current assets. During the same period, investing activities consumed a net $1.7
million principally due to the use of $2.6 million for the purchase of
INOVOJECT(R) systems to accommodate domestic and international growth.
Net financing activities consumed $2.3 million during the period largely as a
result of repayments on capital lease obligations. In addition, proceeds from
the exercise of options to purchase common stock provided $307,000.
As of September 30, 1997 the Company had outstanding purchase commitments of
approximately $2.7 million related to the production of the Company's
Bursaplex(TM) product, and materials and supplies for the construction and
maintenance of INOVOJECT(R) egg injection systems. Additionally, in connection
with the January 1996 agreement reached with Select Laboratories (as discussed
in the Company's Form 10-K for the year ended December 31, 1996), the Company is
obligated to purchase all existing inventories of raw material, Bursaplex(TM),
and related materials from Select within thirty months following the January 20,
1997 receipt of IN OVO approval of the Bursaplex(TM) product being manufactured
for Embrex.
Based on its current operations, management believes that its available cash and
short-term investments, together with cash flow from operations and existing
equipment financing lines, will be sufficient to meet its foreseeable cash
requirements.
FORWARD-LOOKING STATEMENTS
This report contains "forward-looking" statements. These statements involve
risks and uncertainties that could cause the Company's actual results to differ
materially from those in the forward looking statements, including without
limitation the Company's dependence on certain customers; the ability of the
Company, its manufacturing and marketing partners and others to obtain
regulatory approval for products to be delivered IN OVO, which are dependent on
a number of factors, including the results of trials, the discretion of
regulatory officials, and any potential changes in regulations; the Company's
ability to generate future cash flow from operations; continued demand for the
INOVOJECT(R) system; the successful outcome of patent litigation; the Risk
Factors described in the Company's Form 10-K for the year ended December 31,
1996 (Exhibit 99); and other risks detailed from time to time in the Company's
Securities and Exchange Commission filings, including the Company's reports on
Forms 10-Q, 10-K, and 8-K.
9
<PAGE>
Item 3. Quantitative and Qualitative Disclosures About Market Risk. Not
applicable.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
For a description of certain patent infringement proceedings initiated by the
registrant and related legal proceedings, see registrant's Form 10-K for the
year ended December 31, 1996 filed with the Securities and Exchange Commission
on March 31, 1997, as amended by Form 10-K/A filed with the Securities and
Exchange Commission on April 15, 1997.
Item 2. Changes in Securities.
During 1997, $425,000 of outstanding debentures along with $66,000 of accrued
interest were converted into 98,267 shares of Common Stock net of unamortized
debt issuance costs totaling $1,000 pursuant to a claim of exemption from
registration under Section 3(a)(9) of the Securities Act of 1933, as amended. In
addition, 419 shares of Embrex Common Stock were issued pursuant to the non-cash
exercise of outstanding warrants (which were originally issued to the placement
agent for such debentures), pursuant to a claim of exemption from registration
under Section 4(2) of the Securities Act of 1933, as amended, based on the
private nature of the transaction, not involving a public offering, with a
limited number of individuals.
Item 3. Defaults Upon Senior Securities. Not applicable.
Item 4. Submission of Matters to a Vote of Security Holders. Not applicable.
Item 5. Other information.
As previously announced, Embrex has completed an amendment to its contract with
Tyson Foods, Incorporated to extend its relationship through December 31, 2004.
The amendment also provides for termination only upon twelve months notice by
either party (as provided in the existing contract), and a right of first
refusal for Embrex to meet any offer being considered by Tyson for any method of
chick vaccination.
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
27 - Financial Data Schedule.
(b) Reports on Form 8-K. Not applicable.
10
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: November 10, 1997
EMBREX, INC.
By: /s/ Randall L. Marcuson
-------------------------------
Randall L. Marcuson
President and Chief Executive Officer
By: /s/ Don T. Seaquist
--------------------------------
Don T. Seaquist
Vice President, Finance and Administration
<PAGE>
Embrex, Inc.
File No. 000-19495
Form 10-Q
For the Quarterly Period
Ended September 30, 1997
EXHIBIT INDEX
Sequential
Exhibit Page Number
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> SEP-30-1997
<CASH> 9,338
<SECURITIES> 0
<RECEIVABLES> 2,788
<ALLOWANCES> 0
<INVENTORY> 1,862
<CURRENT-ASSETS> 13,988
<PP&E> 24,579
<DEPRECIATION> (13,095)
<TOTAL-ASSETS> 25,472
<CURRENT-LIABILITIES> 6,276
<BONDS> 3,774
0
0
<COMMON> 82
<OTHER-SE> 15,340
<TOTAL-LIABILITY-AND-EQUITY> 25,472
<SALES> 18,377
<TOTAL-REVENUES> 18,377
<CGS> 8,927
<TOTAL-COSTS> 8,927
<OTHER-EXPENSES> 7,566
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 502
<INCOME-PRETAX> 1,382
<INCOME-TAX> 164
<INCOME-CONTINUING> 1,218
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,218
<EPS-PRIMARY> $0.15
<EPS-DILUTED> $0.15
</TABLE>
